Hikma Pharmaceuticals

Hikma Pharmaceuticals has appointed Tobias Hestler, with effect from Thursday, as an independent, non-executive member of the board. Hestler will join the audit, remuneration and nomination and governance committees and is due to take over as chair of the audit committee after the 2027 annual general meeting, succeeding Douglas Hurt. Hestler was most recently Group CFO and Executive Director at Haleon and previously held senior finance roles at GSK and Novartis; he currently sits on the boards of Convatec and Alliance Pharma and is treasurer of the Elton John AIDS Foundation. » Więcej na de.investing.com

Hikma Pharmaceuticals paid a dividend of £0.62 per share for the 2025 financial year; the total payout amounts to £140.38 million, 2.50% above the previous year. The ex-dividend date was 24 April 2026, and the dividend yield for 2025 is 4.03%. Over three years the share price in London fell by 23.94%, but total return (price plus dividends) rose by 31.97%. FactSet analysts expect a dividend of $0.85 per share for 2026, which would lift the yield to about 4.69%. » Więcej na finanzen.net

Hikma has confirmed its 2026 outlook after a first quarter that went as expected. The injectables division is targeting low single-digit revenue growth with an adjusted operating margin of 27–28%, driven by strong US demand for Tyzavan. The US-Rx division also progressed as planned, supported by the launch of a generic tapentadol; expansion projects in Bedford and Columbus are advancing. The company is exiting the 503b compounding business, has repurchased £54.8m of shares up to 17 April, and is monitoring the geopolitical situation in the Middle East while sales remain robust but it faces cost-driven inflationary pressure. » Więcej na de.investing.com